ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Arrowhead Research Corporation (ARWR) Report Updated: Dec 15, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Arrowhead Research Corporation (ARWR)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: REGN, MACK, CBST, ADMA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: C down upgrade
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

Arrowhead Research Corporation© quotemedia

Company Profile

Arrowhead Research Corporation, a clinical stage nanomedicine company, through its subsidiaries, develops therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. It focuses on the design and development of therapeutic agents for the treatment of cancer and obesity, as well as healing wounded or diseased tissue based on nucleic acid delivery, siRNA chemistry, and tissue targeting intellectual properties. The company’s lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism; and Adipotide, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. It also plans to develop its internal preclinical and clinical pipeline, including RONDEL-enabled siRNA drug candidates, Dynamic Polyconjugate (DPC)-enabled drug candidate development, and the non-siRNA-based anti-obesity drug candidate, Adipotide. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.

Recent News: Arrowhead Research Corporation